Literature DB >> 19479341

Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population.

Trude Haugland1, Morten H Vatn, Marijke Veenstra, Astrid Klopstad Wahl, Gerd Karin Natvig.   

Abstract

PURPOSE: Health related quality of life (HRQoL) was characterized among patients with neuroendocrine tumor (NET) and compared with the general Norwegian population.
METHODS: A cross sectional, comparative design was chosen, and the samples comprised 196 NET patients and 5,258 individuals from the general Norwegian population. We used Chi-square cross tab calculations to evaluate sociodemographic characteristics, T-tests for independent samples and Analysis of Variance (ANOVA) in order to compare HRQoL (SF-36) scores across a range of background variables. Furthermore, T-tests were used to analyze differences in HRQoL scores between the samples.
RESULTS: NET patients demonstrated significantly lower on all HRQoL subscales when compared with the general population with the lowest values on general health, physical limitation and vitality. Individuals above 70 years reported lower scores on physical functioning and physical limitations compared with those who were younger. Individuals with higher levels of education reported increased physical functioning compared with those with less education and full-time or part-time workers described higher physical functioning and less physical limitations compared with those who were retired.
CONCLUSIONS: All SF-36 HRQoL scores were significantly lower among the NET patients when compared with the general population. Assistance from health personnel to NET patients should focus on those domains.

Entities:  

Mesh:

Year:  2009        PMID: 19479341     DOI: 10.1007/s11136-009-9487-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  26 in total

1.  Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours.

Authors:  A H G Davies; G Larsson; J Ardill; E Friend; L Jones; M Falconi; R Bettini; M Koller; O Sezer; C Fleissner; B Taal; J M Blazeby; J K Ramage
Journal:  Eur J Cancer       Date:  2006-01-18       Impact factor: 9.162

2.  Short form 36 (SF-36) health survey: normative data from the general Norwegian population.

Authors:  J H Loge; S Kaasa
Journal:  Scand J Soc Med       Date:  1998-12

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Defining and measuring quality of life in medicine.

Authors:  L Frank; L Kleinman; N K Leidy; M Legro; R Shikiar; D Revicki
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

5.  Cancer patient and staff ratings of the importance of caring behaviors and their relations to patient anxiety and depression.

Authors:  G Larsson; V Widmark Peterson; C Lampic; L von Essen; P O Sjödén
Journal:  J Adv Nurs       Date:  1998-04       Impact factor: 3.187

6.  Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours.

Authors:  G Larsson; P O Sjödén; K Oberg; B Eriksson; L von Essen
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

Review 7.  Measurement of quality of life in carcinoid/neuroendocrine tumours.

Authors:  J K Ramage; A H Davies
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

8.  Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.

Authors:  Kjell Oberg; Lone Astrup; Barbro Eriksson; Sture E Falkmer; Ursula G Falkmer; Jens Gustafsen; Caj Haglund; Ulrich Knigge; Morten H Vatn; Matti Välimäki
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

9.  Survival and functional quality of life after resection for hepatic carcinoid metastasis.

Authors:  Clayton D Knox; Irene D Feurer; Paul E Wise; Laura W Lamps; J Kelly Wright; Ravi S Chari; D Lee Gorden; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.267

10.  Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment.

Authors:  Stéphanie Boini; Serge Briançon; Francis Guillemin; Pilar Galan; Serge Hercberg
Journal:  Health Qual Life Outcomes       Date:  2004-01-09       Impact factor: 3.186

View more
  27 in total

1.  Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours.

Authors:  Vanessa L Beesley; Matthew Burge; Monica Dumbrava; Jack Callum; Rachel E Neale; David K Wyld
Journal:  Support Care Cancer       Date:  2018-03-29       Impact factor: 3.603

2.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

3.  Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.

Authors:  Michael S Broder; Eunice Chang; Dorothy Romanus; Dasha Cherepanov; Maureen P Neary
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

4.  Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Authors:  Julie Hallet; Laura E Davis; Alyson L Mahar; Calvin H L Law; Elie Isenberg-Grzeda; Lev D Bubis; Simron Singh; Sten Myrehaug; Haoyu Zhao; Kaitlyn Beyfuss; Lesley Moody; Natalie G Coburn
Journal:  Oncologist       Date:  2019-07-03

5.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Authors:  Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

6.  A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Authors:  Nitya Raj; Elizabeth Cruz; Sarah O'Shaughnessy; Claudia Calderon; Joanne F Chou; Marinela Capanu; Olivia Heffernan; April DeMore; Sippy Punn; Tiffany Le; Haley Hauser; Leonard Saltz; Diane Reidy-Lagunes
Journal:  JCO Oncol Pract       Date:  2022-06-20

Review 7.  Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.

Authors:  Elsa M Ronde; Charlotte M Heidsma; Anne M Eskes; Josefine E Schopman; Elisabeth J M Nieveen van Dijkum
Journal:  Eur J Cancer Care (Engl)       Date:  2021-08-30       Impact factor: 2.328

8.  Symptomatic Control of Neuroendocrine Tumours with Everolimus.

Authors:  Hannah E Bainbridge; Emmanuel Larbi; Gary Middleton
Journal:  Horm Cancer       Date:  2015-08-06       Impact factor: 3.869

9.  Health-Related Quality of Life, Subjective Health Complaints, Psychological Distress and Coping in Pakistani Immigrant Women With and Without the Metabolic Syndrome : The InnvaDiab-DEPLAN Study on Pakistani Immigrant Women Living in Oslo, Norway.

Authors:  Victoria Telle Hjellset; Camilla M Ihlebæk; Benedikte Bjørge; Hege R Eriksen; Arne T Høstmark
Journal:  J Immigr Minor Health       Date:  2011-08

10.  Improvement in Stress, General Self-Efficacy, and Health Related Quality of Life following Patient Education for Patients with Neuroendocrine Tumors: A Pilot Study.

Authors:  Trude Haugland; Marijke Veenstra; Morten H Vatn; Astrid K Wahl
Journal:  Nurs Res Pract       Date:  2013-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.